6/17
12:08 pm
gmab
EHA2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma [Yahoo! Finance]
Low
Report
EHA2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma [Yahoo! Finance]
6/16
09:29 pm
gmab
EHA 2024: Roche's Columvi competes in BiTE battle with positive results in DLBCL [Yahoo! Finance]
Low
Report
EHA 2024: Roche's Columvi competes in BiTE battle with positive results in DLBCL [Yahoo! Finance]
6/10
10:16 am
gmab
Ovarian Cancer Pipeline Drugs Analysis, 2024: Insights on 180+ Companies and 200+ Pipeline Drugs, Including Atezolizumab (Genentech), Tisotuma Vedotin (Genmab), and SON-1010 (Sonnet Biotherapeutics) [Yahoo! Finance]
Low
Report
Ovarian Cancer Pipeline Drugs Analysis, 2024: Insights on 180+ Companies and 200+ Pipeline Drugs, Including Atezolizumab (Genentech), Tisotuma Vedotin (Genmab), and SON-1010 (Sonnet Biotherapeutics) [Yahoo! Finance]
6/4
09:05 am
gmab
Genmab A/S (NASDAQ: GMAB) had its price target raised by analysts at Truist Financial Co. from $50.00 to $53.00. They now have a "buy" rating on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its price target raised by analysts at Truist Financial Co. from $50.00 to $53.00. They now have a "buy" rating on the stock.
6/3
09:24 am
gmab
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) [Yahoo! Finance]
Low
Report
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) [Yahoo! Finance]
6/3
09:00 am
gmab
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Low
Report
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
6/3
08:03 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
6/3
05:12 am
gmab
Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC [Yahoo! Finance]
Low
Report
Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC [Yahoo! Finance]
6/2
05:37 pm
gmab
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma [Yahoo! Finance]
Low
Report
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma [Yahoo! Finance]
6/2
05:30 pm
gmab
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
Low
Report
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
6/1
10:10 am
gmab
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) [Yahoo! Finance]
Low
Report
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) [Yahoo! Finance]
6/1
10:00 am
gmab
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Low
Report
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
5/23
05:03 pm
gmab
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Medium
Report
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
5/23
05:00 pm
gmab
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Medium
Report
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
5/22
08:19 am
gmab
Genmab acquires biotechnology company ProfoundBio in $1.8bn deal [Yahoo! Finance]
Low
Report
Genmab acquires biotechnology company ProfoundBio in $1.8bn deal [Yahoo! Finance]
5/21
11:15 am
gmab
Genmab Completes Acquisition of ProfoundBio [Yahoo! Finance]
Low
Report
Genmab Completes Acquisition of ProfoundBio [Yahoo! Finance]
5/21
11:10 am
gmab
Genmab Completes Acquisition of ProfoundBio
Low
Report
Genmab Completes Acquisition of ProfoundBio
5/21
11:06 am
gmab
Genmab Completes Acquisition of ProfoundBio
Low
Report
Genmab Completes Acquisition of ProfoundBio
5/20
08:03 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
5/14
10:15 am
gmab
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress [Yahoo! Finance]
Low
Report
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress [Yahoo! Finance]
5/14
10:05 am
gmab
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
Low
Report
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
5/3
12:53 pm
gmab
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/2
11:07 am
gmab
Genmab Announces Financial Results for the First Quarter of 2024 [Yahoo! Finance]
Low
Report
Genmab Announces Financial Results for the First Quarter of 2024 [Yahoo! Finance]
5/2
11:01 am
gmab
Genmab Announces Financial Results for the First Quarter of 2024
Low
Report
Genmab Announces Financial Results for the First Quarter of 2024
5/1
10:42 am
gmab
Genmab: A Complicated Tale [Seeking Alpha]
Low
Report
Genmab: A Complicated Tale [Seeking Alpha]